drugset / Trial / NCT00717093
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary goal of this study is to compare efficacy of varenicline to placebo for cessation of use of smokeless tobacco.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-04
- Completion
- 2009-07
Outcome
Met primary endpoint
registry Varenicline Tartrate vs Placebo; p <0.0001; Odds Ratio (OR) 2.39 (95% CI 1.59 to 3.58) NCT00717093 ↗
paper Continuous abstinence rate at week 9-12 was higher in the varenicline group than the placebo group PMID 21134997 ↗
Publications
- Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
- Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ. 2010 Dec 6;341:c6549. doi: 10.1136/bmj.c6549.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 1 mg | — |